Pharmafile Logo
Pharmafocus logo
Advanced Search

Takeda

Showing 15 posts of 249 posts found.

takeda_usa_pharmaceuticals_u

Takeda’s subcutaneous formulation of Entyvio smashes primary endpoint in Crohn’s disease

July 23, 2019
Manufacturing and Production, Research and Development Crohn’s disease, Entyvio, Takeda, crohn's disease, pharma

Takeda has unveiled new Phase 3 data for a subcutaneous formulation of its gut-selective biologic Entyvio (vedolizumab), showing that the …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

June 28, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Allergan, Bristol-Myers Squibb, China, GSK, Novartis, Takeda, brexit

This week was diverse as always in terms of news coming out of the pharma industry, but the biggest news …

News
takeda_deerfield_hq

Takeda plans to vacate all 1,000 staff from US HQ by the year’s end

June 26, 2019
Manufacturing and Production, Medical Communications, Sales and Marketing Shire, Takeda, US, pharma

Takeda has announced its plans to vacate all staff from its US headquarters in Deerfield, Illinois, by the end of …

News
entrance_takeda_i020_v1

Takeda’s Ninlaro fails to meet one of two primary endpoints in Phase 3 trial

June 6, 2019
Research and Development TOURMALINE-AL1, Takeda, pharma, phase 3, trial Ninlaro

Takeda has decided to discontinue its Phase 3 study of Ninlaro (ixazomib) after the drug in combination with dexamethasone, failed …

News
takeda_usa_pharmaceuticals_u

Takeda’s Entyvio beats Humira for remission in ulcerative colitis, exploratory data show

May 20, 2019
Research and Development, Sales and Marketing AbbVie Humira, Entyvio, Takeda, pharma, ulcerative colitis

Takeda has unveiled exploratory data on its gut-selective biologic drug Entyvio (vedolizumab) at the 2019 Digestive Disease Week, demonstrating its …

News
novartis_window

Novartis buys dry eye treatment Xiidra in deal worth $5.3 billion

May 9, 2019
Business Services, Medical Communications, Sales and Marketing Novartis, Shire, Takeda, debt, pharma, xiidra

Japanese multinational Takeda Pharmaceutical has agreed to sell its dry eye drug Xiidra to Swiss firm Novartis in a deal …

News

Takeda opens R&D facility in San Diego, California

May 2, 2019
Manufacturing and Production, Research and Development CNS, GI, Japan, Takeda, california, neuroscience, san diego

Japanese-firm Takeda pharmaceuticals has opened a new research facility in San Diego, California. The 165,000ft2 research centre will employ 250 …

News
takeda_usa_pharmaceuticals_u

NICE recommend Takeda’s lymphoma treatment Adcetris

March 25, 2019
Sales and Marketing Cancer, NICE, Takeda, UK, lymphoma, oncology, recommendation

Britain’s cost effectiveness body has recommended Takeda’s Adcetris (brentuximab vedotin) for adult patients with CD-30 positive advanced cutaneous T-cell lymphoma …

News
takeda_usa_pharmaceuticals_u

Takeda’s Adcetris secures expanded approval in Europe for untreated CD30+ Stage IV Hodgkin lymphoma

February 14, 2019
Sales and Marketing Adcetris, Cancer, Europe, Hodgkin lymphoma, Takeda, pharma

Takeda’s Adcetris (brentuximab vedotin) has seen its marketing authorisation expanded by the European Commission to include the treatment of previously …

News
shirelabsus

Takeda ordered to pay Bayer $155.19 million over patent infringement

February 6, 2019
Research and Development Baxalta, Bayer, Nektar Therapeutics, Takeda, adynovate

A US court has ordered Takeda Pharmaceutical’s Baxalta unit to pay German firm Bayer AG $155.19 million for infringement of …

News
takeda_usa_pharmaceuticals_u

Takeda’s dengue vaccine proves efficacious in massive Phase 3 trial

January 30, 2019
Research and Development Dengue fever, TAK-003, Takeda, Vaccine, dengue, health, infectious diseases

Takeda’s dengue vaccine candidate TAK-003, has proved efficacious in preventing dengue fever in healthy children and adolescents in an ongoing …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

January 11, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Bristol-Myers Squibb, Shire, Takeda, bristol myers squibb, death row, pharma, top 10

With the completion of Takeda’s £46 billion acquisition of Shire finally done, another even bigger merger was announced as US …

News
takeda_global_hq

Takeda completes Shire acquisition

January 8, 2019
Manufacturing and Production M&A, MA, Shire, Takeda, acquisition, deal, pharma

Japanese firm Takeda Pharmaceuticals has successfully completed its acquisition of Shire Plc. The long anticipated deal has propelled the firm …

News
takeda_usa_pharmaceuticals_u

Takeda unveils three new discovery and development collaborations in immuno-oncology

January 4, 2019
Medical Communications, Research and Development CAR-T, Crescendo Biologics, Memorial Sloan Kettering Cancer Center, Noile-Immune, Takeda, pharma

Takeda has revealed that it is set to bolster its novel immuno-oncology portfolio with three new research collaborations. The Japanese …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

December 7, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Cancer, Diagnostics, Sanofi, Takeda, brexit

Takeda’s acquisition of Shire finally got the go-ahead this week as 88% of shareholders voted in favour of French CEO …

News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026